GM-CSF, Fosfomycin and Metronidazole for Pouchitis in Ulcerative Colitis Patients After Restorative IPAA Surgery

A Combined Treatment With GM-CSF, Fosfomycin and Metronidazole for Pouchitis in Ulcerative Colitis Patients After Restorative Ileal Pouch Anal Anastomosis Surgery

This study will examine whether the application of GM-CSF, fosfomycin and metronidazole locally in the pouch is safe and effective in the treatment of pouchitis for patients with ulcerative colitis, and whether treatment changes the microbiome of the pouch.

Study Overview

• Status: Recruiting
• Conditions: Pouchitis
• Intervention / Treatment: Drug: GM-CSF, fosfomycin and metronidazole

Detailed Description

A definitive cure for patients with treatment-refractory ulcerative colitis is proctocolectomy with IPAA (restorative ileal pouch anal anastomosis). Up to 50% of all patients develop "pouchitis" within the first five years after surgery, an inflammatory condition that is as yet poorly understood and without official consensus on treatment. Treatment modalities include oral antibiotics as well as immunomodulators, steroids, probiotics and biological agents, but up to 20% of these patients develop chronic, treatment-resistant pouchitis, which can result in pouch failure and the need for reoperation with the possible creation of an ileostomy.

The etiology of pouchitis is thought to be similar to other inflammatory bowel diseases, in that genetic and bacterial factors, a compromised gastrointestinal barrier and immunological components seem to play a role. Its pathogenetic mechanisms seem to mimic Crohn's disease, in which smaller studies have shown some effect of systemically administered GM-CSF (granulocyte-macrophage colony stimulating factor) on the gut macrophage function in clearing microorganisms and maintaining the mucosal barrier.

The investigators hypothesize that GM-CSF will have an effect in the treatment of pouchitis because of its similarity to that of Crohn's disease. In order to maximize effect on the inflamed mucosa and minimize systemic side effects, the study drug will be administered locally in the pouch. In a safety and proof-of-concept intervention study, 50 µg GM-CSF will be combined with 400 mg Fosfomycin and 100 mg Metronidazole, to target both the suspected immunological as well as the bacterial role in the pathogenesis of pouchitis.

The effect on the pouch will be assessed endoscopically and histologically by taking biopsies that will also be examined for changes in the microbiome. Trial participants will be clinically examined and have blood samples taken to monitor for adverse reactions. The primary outcome measure will be an assessment of adverse reactions and tolerability of the drug. Secondary outcome measures will be a change in the pouchitis disease activity index (PDAI), a change in the microbial diversity, and a change in inflammatory markers.

This study is based on a non-randomized trial design with an open-label single group assignment.

Phase I The tolerability of treatment will be tested on 6 trial participants with pouchitis with a single dose of the combined medication applied endoscopically in the pouch. Endoscopy with the taking of biopsies will be performed before and one week after administration of the medication, as well as blood samples before and after the medication. After the follow-up endoscopy, the trial participant will receive standard oral metronidazole or ciprofloxacin treatment for 10 days.

Phase II Depending on effect of the first study, the second study plans for the treatment of 12 trial participants. Endoscopy with biopsies will be conducted with the first application of the study drug combination in the pouch, and afterward a daily dosage for another 6 days. Clinical and endoscopic control after 14 days with blood samples and biopsies will be done. After the follow-up endoscopy, the trial participant will receive standard oral metronidazole or ciprofloxacin treatment for 10 days.

• Study Type: Interventional
• Enrollment (Anticipated): 18
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Ismail Gögenur, Professor; Phone Number: 0045 26356426; Email: igo@regionsjaelland.dk
• Study Contact Backup: Name: Viviane Lin, MD; Phone Number: 0045 60547025; Email: vial@regionsjaelland.dk

Study Locations

• Denmark
  • Region Zealand
    • Køge, Region Zealand, Denmark, 4600
      • Recruiting
      • Zealand University Hospital
      • Contact: Ismail Gögenur, Professor; Phone Number: 0045 26356426; Email: igo@regionsjaelland.dk
      • Contact: Viviane Lin, MD; Phone Number: 0045 60547025; Email: vial@regionsjaelland.dk

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Of any gender
• Over 18 years of age
• Have a previous diagnosis of ulcerative colitis
• Have had IPAA surgery, and
• Have been diagnosed with pouchitis
• Be able to understand and complete study procedures as determined by the investigator
• Be able to speak either Danish or English
• Be able to comply with study procedures for the length of the study
• Use a highly effective contraception method for the duration of the trial (until day 30 in Phase I and until day 37 in Phase II), such as implants, injectables, oral contraceptives, IUD (intrauterine device), sexual abstinence or vasectomized partner.

Exclusion Criteria:

• Patients with a previous allergic reaction to GM-CSF, metronidazole or fosfomycin
• Patients who are currently under antibiotic treatment or have received antibiotic treatment within the past 30 days
• Patients currently pregnant or breastfeeding
• Patients with ASA IV classification (American Society of Anesthesiologists physical status classification)
• Patients with severe pulmonary disease
• Patients with autoimmune thrombocytopenia
• Patients with severe renal impairment (eGFR < 40 ml/min)
• Patients with alcohol use disorder or history of drug abuse
• Patients currently in treatment for any malignant or hematological disease
• Patients with a previous history of cancer will be excluded from the study (except for patients with well-treated and stabile cancer after a control period of more than two years).
• Patients with anticipated compliance problems as determined by the investigator

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Local administration of GM-CSF, fosfomycin and metronidazole in the pouch; Local administration of 50 micrograms GM-CSF, 400 milligrams fosfomycin and 100 milligrams metronidazole in the pouch. In a Phase A of the trial, this will be applied as a single dose during endoscopy of the pouch. In Phase B of the trial, this will be applied as a first dose during endoscopy of the pouch, followed by 6 further daily doses for a total of 7 doses.

Drug: GM-CSF, fosfomycin and metronidazole; GM-CSF 50 micrograms Fosfomycin 400 milligrams Metronidazole 100 milligrams applied as a gel in the pouch; Other Names: Metronidazole; GM-CSF; Fosfomycin

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Phase 1: safety study, Determine serious adverse reactions or adverse reactions from the application of GM-CSF, metronidazole and fosfomycin in the pouch	Incidence of Treatment-Emergent Adverse Events	30 days after first application of study drug
Phase 2: Proof of concept study, Change in the pouchitis disease activity index (PDAI)	A decrease of 3 points or more will be determined as an improvement in PDAI from before application of the study drug to 7 days after application of the study drug. Between 0-18 points can be given, with a score of 7 or higher indicating pouchitis.	14 days after first application of the study drug

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Phase 1: Change in the pouchitis disease activity index (PDAI)	A decrease of 3 points or more will be determined as an improvement in PDAI from before application of the study drug to 7 days after application of the study drug. Between 0-18 points can be given, with a score of 7 or higher indicating pouchitis.	Within 7 days after application of the study drug
Phase 1: Number of trial participants with a change in median white blood cells after treatment	Change in median white blood cells (numbers × 10^9/L)	Within 7 days after application of the study drug
Phase 1: Number of trial participants with a change in median CRP after treatment	Change in median CRP (mg/L)	Within 7 days after application of the study drug
Phase 1: Number of trial participants with a change in median creatinine after treatment	Change in median creatinine (µmol/L)	Within 7 days after application of the study drug
Phase 1: Number of trial participants with a change in median liver enzymes after treatment	Change in median liver enzymes (ALAT, alanine-aminotransferase in U/L)	Within 7 days after application of the study drug
Phase 1: Change in microbial diversity in the pouch using 16S rRNA sequencing	A qualitative assessment of the microbial diversity of the mucosa of the pouch by determining species names and distribution quantity using 16S rRNA sequencing.	Within 7 days after application of the study drug
Phase 2: Change in the clinical, endoscopic or histological PDAI	A decrease of 3 points or more will be determined as an improvement in PDAI individually for clinical (0-6 points), endoscopic (0-6 points) and histological (0-6 points) PDAI.	14 days after first application of the study drug
Phase 2: Number of trial participants with a change in median white blood cells after treatment	Change in median white blood cells (numbers × 10^9/L)	14 days after first application of the study drug
Phase 2: Number of trial participants with a change in median CRP after treatment	Change in median CRP (mg/L)	14 days after first application of the study drug
Phase 2: Number of trial participants with a change in median creatinine after treatment	Change in median creatinine (µmol/L)	14 days after first application of the study drug
Phase 2: Number of trial participants with a change in median liver enzymes after treatment	Change in median liver enzymes (ALAT, alanine-aminotransferase in U/L)	14 days after first application of the study drug
Phase 2: Change in microbial diversity in the pouch using 16S rRNA sequencing	A qualitative assessment of the microbial diversity of the mucosa of the pouch by determining species names and distribution quantity using 16S rRNA sequencing.	14 days after first application of the study drug
Phase 2: Determine serious adverse reactions or adverse reactions from the application of GM-CSF, metronidazole and fosfomycin in the pouch	Incidence of Treatment-Emergent Adverse Events	37 days after first application of the study drug

Collaborators and Investigators

• Sponsor: Zealand University Hospital
• Investigators: Principal Investigator: Ismail Gögenur, Professor, Zealand University Hospital

Study record dates

Study Major Dates

• Study Start (Actual): September 6, 2021
• Primary Completion (Anticipated): December 1, 2023
• Study Completion (Anticipated): December 1, 2023

Study Registration Dates

• First Submitted: June 30, 2021
• First Submitted That Met QC Criteria: July 16, 2021
• First Posted (Actual): July 28, 2021

Study Record Updates

• Last Update Posted (Estimate): January 26, 2023
• Last Update Submitted That Met QC Criteria: January 25, 2023
• Last Verified: January 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Gastrointestinal Diseases; Gastroenteritis; Colonic Diseases; Intestinal Diseases; Inflammatory Bowel Diseases; Enteritis; Ileitis; Ileal Diseases; Colitis; Colitis, Ulcerative; Pouchitis; Physiological Effects of Drugs; Anti-Infective Agents; Antineoplastic Agents; Immunologic Factors; Anti-Bacterial Agents; Antiprotozoal Agents; Antiparasitic Agents; Metronidazole; Sargramostim; Fosfomycin; Molgramostim
• Other Study ID Numbers: REG-106-2020; 2020-000609-10 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No